45283
document
[ Hepatoprotective activity of remaxol in patients with chronic hepatic disorders ] . This milticentre randomized clinical study of the efficiency of remaxol infusion solution ( hepatoprotective medicine for chronic liver dysfunction ) included 494 patients with chronic hepatitis B and C. 294 of them staying in 7 clinics were given remaxol and 200 ones received placebo . Randomization was achieved by the envelope method . A detailed description of clinical and laboratory characteristics of the diseases is presented . Effects of remaxol vs placebo on the functional activity of affected liver are discussed . Results of laboratory and clinical analysis indicate that mechanism of remaxol action is based on hepatoprotective , antioxidative , and anticholestatic activities of the drug .
45284
Intervention_Pharmacological
remaxol
45285
Intervention_Pharmacological
remaxol infusion solution
45286
Intervention_Pharmacological
remaxol
45287
Intervention_Control
placebo
45288
Intervention_Pharmacological
remaxol
45289
Intervention_Control
placebo
45290
Intervention_Pharmacological
remaxol
45291
Outcome_Physical
Hepatoprotective activity
45292
Outcome_Other
efficiency
45293
Outcome_Physical
functional activity
45294
Outcome_Physical
hepatoprotective , antioxidative , and anticholestatic activities
45295
Participant_Condition
chronic hepatic disorders
45296
Participant_Condition
494 patients
45297
Participant_Condition
chronic hepatitis B and C.
45298
Participant_Condition
7 clinics